Prognostic impact of postoperative C-reactive protein level in patients with metastatic renal cell carcinoma undergoing cytoreductive nephrectomy
- PMID: 18550105
- DOI: 10.1016/j.juro.2008.04.025
Prognostic impact of postoperative C-reactive protein level in patients with metastatic renal cell carcinoma undergoing cytoreductive nephrectomy
Abstract
Purpose: We explored the prognostic impact of C-reactive protein status in patients with metastatic renal cell carcinoma undergoing cytoreductive nephrectomy.
Materials and methods: The oncological outcome of 40 patients with metastatic renal cell carcinoma (TxpN1M0, TxNxM1) who underwent cytoreductive nephrectomy was analyzed. The C-reactive protein level was measured before and 1 month after cytoreductive nephrectomy. The normal value of C-reactive protein was considered less than 0.5 mg/dl.
Results: During the median followup of 14 months 31 patients (78%) died of the disease. The preoperative C-reactive protein level was not increased in 17 of the 40 patients (nonelevated group). Of the remaining 23 patients with a preoperatively increased C-reactive protein level, after cytoreductive nephrectomy the C-reactive protein level normalized in 17 (normalized group). However, in the remaining 6 patients the C-reactive protein level did not normalize and remained high during followup (nonnormalized group). All of the patients in nonnormalized group died of the disease within 1 year. The overall survival rate of the nonnormalized group was significantly worse than that of the other 2 groups (p <0.0001). No significant difference was found in terms of overall survival rate between the normalized and nonelevated groups (p = 0.22). Multivariate analysis demonstrated that nonnormalized C-reactive protein (p <0.0001), absence of metastatectomy (p = 0.005), poorer performance status (p = 0.006) and bone metastases (p = 0.023) were independent factors for predicting poorer overall survival.
Conclusions: The current study indicated that C-reactive protein kinetics would predict the clinical course of patients with metastatic renal cell carcinoma who underwent cytoreductive nephrectomy. Larger confirmatory studies would be warranted to validate the current results.
Comment in
-
Renal masses--to treat or not to treat? If that is the question are contemporary biomarkers the answer?J Urol. 2008 Aug;180(2):433-4. doi: 10.1016/j.juro.2008.04.124. Epub 2008 Jun 11. J Urol. 2008. PMID: 18550098 Free PMC article. No abstract available.
Similar articles
-
Impact of C-reactive protein kinetics on survival of patients with metastatic renal cell carcinoma.Eur Urol. 2009 May;55(5):1145-53. doi: 10.1016/j.eururo.2008.10.012. Epub 2008 Oct 14. Eur Urol. 2009. PMID: 18930583
-
Absolute preoperative C-reactive protein predicts metastasis and mortality in the first year following potentially curative nephrectomy for clear cell renal cell carcinoma.J Urol. 2010 Feb;183(2):480-5. doi: 10.1016/j.juro.2009.10.014. Epub 2009 Dec 14. J Urol. 2010. PMID: 20006861
-
Lack of retroperitoneal lymphadenopathy predicts survival of patients with metastatic renal cell carcinoma.J Urol. 2001 Jul;166(1):68-72. J Urol. 2001. PMID: 11435825
-
Surgical intervention in patients with metastatic renal cancer: metastasectomy and cytoreductive nephrectomy.Urol Clin North Am. 2008 Nov;35(4):679-86; viii. doi: 10.1016/j.ucl.2008.07.009. Urol Clin North Am. 2008. PMID: 18992621 Review.
-
Cytoreductive nephrectomy in metastatic renal cell carcinoma.Expert Rev Anticancer Ther. 2006 Aug;6(8):1295-304. doi: 10.1586/14737140.6.8.1295. Expert Rev Anticancer Ther. 2006. PMID: 16925495 Review.
Cited by
-
C-reactive protein as a biomarker for urological cancers.Nat Rev Urol. 2011 Oct 25;8(12):659-66. doi: 10.1038/nrurol.2011.145. Nat Rev Urol. 2011. PMID: 22025173 Review.
-
The Predictive Value of Inflammation-Related Peripheral Blood Measurements in Cancer Staging and Prognosis.Front Oncol. 2018 Mar 21;8:78. doi: 10.3389/fonc.2018.00078. eCollection 2018. Front Oncol. 2018. PMID: 29619344 Free PMC article. Review.
-
Approach to the small renal mass: weighing treatment options.Curr Urol Rep. 2009 Jan;10(1):11-6. doi: 10.1007/s11934-009-0004-0. Curr Urol Rep. 2009. PMID: 19116090
-
Postoperative renormalization of C-reactive protein with adjuvant lienal polypeptide and its association with tumour recurrence in T1 clear cell renal cell carcinoma.J Int Med Res. 2016 Jun;44(3):620-6. doi: 10.1177/0300060515621640. Epub 2016 Mar 4. J Int Med Res. 2016. PMID: 26944387 Free PMC article.
-
Development and validation of nomograms and integrated software incorporating preoperative C-reactive protein level for prognostic prediction of nonmetastatic clear cell renal cell carcinoma: Results from the International Marker Consortium for Renal Cancer (INMARC) Registry.World J Urol. 2025 Jan 9;43(1):63. doi: 10.1007/s00345-024-05421-3. World J Urol. 2025. PMID: 39786437
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials